- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT03123874
Milk in Life Conditions (MiLC): Bacterial Composition of Human Milk Pumped and Stored in "Real-Life" Conditions (MiLC)
Milk in Life Conditions (MiLC): Characterizing the Bacterial Composition of Human Milk Pumped and Stored in "Real-life" Conditions
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Participants will donate 1 oz of human milk during each of two consecutive pumping sessions, for a total volume of 2 oz donated on one day. To collect this human milk, participants will be asked to fully express one breast during each pumping session. Participants will pump once with the participant's own pump set-up and once with the sterile pump set-up (provided by the research team). Women will be randomized to which pump is used first.
Randomization will be done using stratified randomization as follows: participants were stratified by how their infants were fed, namely whether infants were fed human milk only vs. human milk and complementary foods). Then, randomization was conducted within each strata. The researchers aim to have a minimum of 25 participants in each stratum.
All human milk collections will occur at participants' homes between 0700 and 1100 hours. The second pumping session must begin 3 hours (+/-30 minutes) after the beginning of the first pumping session (e.g. the first pumping session at 7:30 am and the second at 10:30 am). Participants will elect from which breast to donate human milk and that breast will be used for both pumping sessions. Participants will be asked not to nurse from or pump that breast during the 2 hours before the first pumping session and not until after the second pumping session (a total of ~5.5 hours).
From the milk produced during each pumping session (which could be up to ~6 oz), researchers will collect 1 oz using a sterile, plastic syringe. Participants will keep the remaining volume of milk. Each ounce of milk collected will be separated into 5 sterile containers (provided). Participants will store donated milk at home until it is picked up by a researcher 2, 4, and 30 days after pumping.
Studietyp
Inskrivning (Faktisk)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
New York
-
Ithaca, New York, Förenta staterna, 14853
- Hay Laboratory, B75C Wing Hall, Cornell University
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Lactating women over the age of 18 years
- Self-reported as healthy women and infants
- Use an electric breast pump
- Confident of ability to donate 1 oz of milk from one breast during each of two consecutive pumping sessions where pumping sessions are 3 hours (+/- 30 minutes) apart and between 0700-1100 hours.
- Able to store donated milk at home for 30 days
- Have infants who do not consume formula or only consume formula episodically as long as the most recent formula-feeding occurred > 2 weeks before the day milk is pumped for this study.
Exclusion Criteria:
- Not confident of ability to donate 1 oz of milk from one breast during each of two consecutive pumping sessions, 3 hours (+/- 30 minutes) apart and between the hours of 0700-1100 hours.
- Infant consumption of formula in the past 2 weeks
- Current indication of breast infection (e.g., breast pain, discomfort, lumps, mastitis with fever, red streaks, or hard red portions of the breast)
- Breast pain that the woman does not consider "normal" for lactation/breastfeeding
- Signs/symptoms of acute illness in woman or infant in past 7 days including fever (rectal or temporal temperature ≥99.5 F), dark green nasal discharge, diarrhea (abrupt onset of 3 or more excessively "loose" stools in one day), vomiting (where infant vomiting is not associated with feeding), or severe cough.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Grundläggande vetenskap
- Tilldelning: Randomiserad
- Interventionsmodell: Crossover tilldelning
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Sterile pump set-up first
Participants will pump with sterile pump set-ups first.
Approximately 3 hours later, participants will pump with their own pump set-ups.
|
Medela symphony breast pump (model number 0240108) and disposable, sterile collection kits (model number 67399S).
Mother's own electric breast pump and own collection kit (previously used and cleaned at home using her usual practices).
|
|
Experimentell: Mother's Own pump set-up first
Participants will pump with their own pump set-ups first.
Approximately 3 hours later, participants will pump with sterile pump set-ups.
|
Medela symphony breast pump (model number 0240108) and disposable, sterile collection kits (model number 67399S).
Mother's own electric breast pump and own collection kit (previously used and cleaned at home using her usual practices).
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Bacterial Community Richness
Tidsram: 0 days after pumping
|
Richness is the total number of different bacterial taxa detected in the sample.
This metric will be assessed on data collected via high-throughput sequencing of the bacterial 16S rRNA gene present in milk.
|
0 days after pumping
|
|
Bacterial Community Diversity
Tidsram: 0 days after pumping
|
Bacterial community diversity will be assessed using the the Shannon diversity index.
The Shannon diversity index is a type of entropy measure and is a function of the distribution of the total number of organisms across all of the species.
If S is the total number of species in the sample and p_i is the number of organisms in the i-th species divided by the total number of organisms, then Diversity = -Σ p_i log(p_i).
This metric will be assessed on data collected via high-throughput sequencing of the bacterial 16S rRNA gene present in milk.
|
0 days after pumping
|
|
Total Live Aerobic Bacterial Counts
Tidsram: 0 days after pumping
|
Number of live total aerobic bacteria in milk assessed by aerobic culturing of milk on plate count agar.
Reported as colony-forming units (CFU)/mL.
|
0 days after pumping
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Kathleen M. Rasmussen, ScD, Cornell University
- Huvudutredare: Anthony Hay, PhD, Cornell University
- Studierektor: Sarah Reyes, MS, Cornell University
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- IRB #: 1608006566
- 2T32DK007158-42 (U.S.S. NIH-anslag/kontrakt)
- NYC-399436 (Annat bidrag/finansieringsnummer: NIFA/USDA)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Bakteriell tillväxt
-
BioVersys SASBioVersys AGRekryteringHospital Acquired Bacterial Pneumonia (HABP) | Ventilatorassocierad bakteriell lunginflammation (VABP) | Acinetobacter Baumannii-calcoaceticus Complex | Colistinresistent ABCGeorgien
-
Yonsei UniversityAvslutadFibroblast Growth Factors (FGFs)/Fibroblast Growth Factor Receptors (FGFRs) Genetic Aberration Gastric Cancer, INCB054828, PaclitaxelKorea, Republiken av
-
Chang Gung Memorial HospitalAvslutadParonychia | Epidermal Growth Factor Receptor InhibitorTaiwan
-
Taipei Medical University WanFang HospitalAvslutadParonychia | Epidermal Growth Factor Receptor InhibitorTaiwan
-
Forest LaboratoriesIndragenCommunity-acquired Bacterial Pneumonia (CABP)
-
WockhardtACMAvslutadCommunity-acquired Bacterial Pneumonia (CABP)Förenta staterna
-
Furiex Pharmaceuticals, IncAvslutadCommunity-acquired Bacterial Pneumonia (CABP)Förenta staterna, Kanada, Colombia, Tyskland, Ungern, Polen
-
Reshma L. Mahtani, D.O.Gilead SciencesRekryteringBröstcancer | Avancerad bröstcancer | Metastaserad bröstcancer | Hormonreceptorpositiv bröstcancer | Human Epidermal Growth Factor 2 Låg bröstcancerFörenta staterna
-
Astellas Pharma Global Development, Inc.Medivation LLC, a wholly owned subsidiary of Pfizer Inc.AvslutadAvancerad bröstcancer | HER2 förstärkt | Human Epidermal Growth Factor Receptor 2 (HER2)Förenta staterna, Belgien, Kanada, Italien, Spanien, Storbritannien
-
Vanderbilt University Medical CenterAvslutadNormalt tryck HydrocephalusFörenta staterna
Kliniska prövningar på Sterile pump set-up
-
Atlanta Diabetes AssociatesMedtronicRekrytering
-
Dana-Farber Cancer InstituteColumbia University; Boston Children's Hospital; McMaster University; University... och andra samarbetspartnersAvslutad
-
Children's Oncology GroupNational Cancer Institute (NCI)AvslutadLeukemiFörenta staterna, Australien, Kanada